Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

NCT06141109 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Safety Issues
Efficacy
MTD

Interventions

DRUG: Sintilimab 200mg+MB07133 600mg

Sponsor

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Collaborators

[object Object]